Slingshot Bio Taps Operations Veteran Dr. Nimisha Srivastava as New CEO

EMERYVILLE, Calif. – September 25, 2026 — The evolution of a life sciences startup typically follows a predictable executive cadence. First comes the visionary founder who births the intellectual property and proves the core science. Next arrives the commercial veteran, brought in to establish market validation, build out the initial sales funnel, and forge enterprise partnerships. Finally, as demand surges and the product must be delivered flawlessly at mass scale, the company turns to the operational architect—the leader tasked with scaling the technology into an industrialized, highly reproducible pipeline.

This week, Slingshot Biosciences signaled its definitive entry into this critical third phase. The Emeryville-based synthetic biology company, recognized as a leader in precision-engineered cell mimics for flow cytometry, announced the appointment of Dr. Nimisha Srivastava as its new Chief Executive Officer, effective September 23, 2026. Dr. Srivastava, who previously served as the company's Chief Operating Officer, succeeds Glenn Bilawsky in a leadership transition that highlights a broader industry trend: in the modern biotech landscape, operational scale-up has become the ultimate commercial strategy.

The Biomanufacturing Imperative

To understand the significance of Dr. Srivastava's appointment, one must look at the trajectory of Slingshot Biosciences over the past two years. In May 2025, the company appointed Glenn Bilawsky as CEO, succeeding founder Dr. Jeffrey Kim. Bilawsky brought a classic commercialization pedigree, having previously led Discovery Life Sciences through thirteen strategic acquisitions and expanded global operations at i3. During his roughly sixteen-month tenure, Bilawsky successfully executed his mandate, transitioning Slingshot from a research catalog provider to an enterprise partner with multi-year supply agreements in the clinical trial and biopharma sectors.

However, as Slingshot's customer base expanded into high-throughput automated manufacturing and cell therapy diagnostics, the company's internal demands shifted. The market no longer just needed a novel product; it required semiconductor-grade lot-to-lot consistency, rapid high-throughput manufacturing, and seamless automation integration.

By elevating Dr. Srivastava, the Board of Directors has chosen an internal operator deeply integrated with the engineering team to bridge the gap between commercial scaling and biomanufacturing execution. Dr. Srivastava brings a formidable technical pedigree to the corner office. Armed with a Ph.D. in Chemical Engineering from the University of Michigan, she spent over a decade as a foundational member of the engineering team at Twist Bioscience. There, rising to Senior Vice President of Research and Development, she architected the automated robotic liquid-handling pipelines that moved synthetic DNA and RNA manufacturing from cumbersome microplates to high-density semiconductor silicon chips.

"Nimisha has played a central role in executing our strategy, supporting our teams, advancing our business priorities, and building strong relationships across the organization," said Nicolas Barthelemy, Chairman of the Board of Slingshot Biosciences, in the official press release. "Her deep understanding of our technology, customers, people, and business positions her well to lead Slingshot into its next phase. The Board has full confidence in her leadership and looks forward to supporting her as we continue to build the company."

Solving the Flow Cytometry Reproducibility Crisis

The urgency behind Slingshot's operational scale-up is driven by a massive, longstanding bottleneck in life sciences: the flow cytometry quality control crisis. Flow cytometry, a technology that analyzes tens of thousands of cells per second using laser scatter and multi-fluorophore antibody panels, is the backbone of modern diagnostics and cell therapy. Yet, historically, the discipline has suffered from severe inter-laboratory variability due to its reliance on flawed biological reference materials.

For decades, researchers and clinical lab directors have relied on donor peripheral blood mononuclear cells (PBMCs) or lyophilized blood as controls. These materials are highly susceptible to preparation artifacts, biohazardous handling requirements, and extreme donor-to-donor variability. Their shelf life is often measured in mere days or weeks, creating a constant logistical nightmare of cold-chain supply.

Cultured tumor cell lines offer little reprieve. While they provide a more consistent baseline, they are plagued by epigenetic and phenotypic drift. Industry data demonstrates that standard target cells used in CAR-T therapy development, such as Raji cell lines, can lose critical surface antigen density—like CD19—as early as their second passage. This instability risks flawed potency assessments and devastating batch rejections during multi-million-dollar cell therapy manufacturing runs.

Even polystyrene calibration beads, long the industry standard for instrument calibration, fall short. As rigid, solid-core particles, they lack natural cellular refractivity and scatter properties, often distorting spectral unmixing in advanced high-parameter spectral flow cytometry.

Slingshot Biosciences has engineered a way out of this paradigm. The company's synthetic cell mimics—marketed under brands like TruCytes and FlowCytes—are precision-engineered polymer particles that reproduce the exact forward and side scatter signatures of living cells. More importantly, they feature fixed, exact biomarker densities. Under Dr. Srivastava's tenure as COO, the company streamlined the manufacturing of these targeted antigen scaffolds to achieve coefficients of variation as low as 0.1 percent. Furthermore, these non-biohazardous, lyophilized mimics boast a shelf life of up to three years at ambient temperatures, entirely eliminating cold-chain bottlenecks.

Regulatory Tailwinds and Automated Horizons

Dr. Srivastava assumes the CEO role at a moment when regulatory and institutional tailwinds are strongly favoring synthetic biology controls. Regulatory bodies, including the FDA and EMA, are increasingly mandating rigorous, quantitative potency and identity assays for the commercial release of autologous and allogeneic cell therapies. Traceable, highly reproducible reference materials are no longer a luxury; they are a regulatory necessity to ensure calibration across decentralized, multi-site clinical trials without the need for endless bridging studies.

Institutions are taking note. The National Institute of Standards and Technology (NIST) recently launched a Flow Cytometry Standards Consortium aimed specifically at establishing quantitative reference standards for advanced cell and gene therapies. Slingshot's synthetic mimics are perfectly positioned to become the gold standard in this newly regulated landscape.

The demand for these synthetic controls is also being driven by the rise of automated manufacturing. In late 2025, Slingshot secured a pivotal partnership with Cellares, integrating its TruCytes Biomarker Controls into the Cellares Cell Q platform. As the industry's first automated quality control station, designed to run in parallel with the FDA-designated Cell Shuttle, the Cell Q platform requires standardized reagents that can support round-the-clock robotic workflows without the downtime associated with donor-control variability. Fulfilling the volume and precision demands of partners like Cellares requires exactly the kind of industrialized reagent manufacturing expertise that Dr. Srivastava honed at Twist Bioscience.

Backed by top-tier venture capital, including a recent $11 million Series A3 round that brought total disclosed funding to nearly $50 million from heavyweights like ARCH Venture Partners and Northpond Ventures, Slingshot has the capitalization required to fund this aggressive expansion. The company has already begun expanding its direct commercial and distribution channels into the United Kingdom and the European Union, shifting from a North American focus to global multi-channel delivery.

The Operator's Era

The leadership transition at Slingshot Biosciences is reflective of a maturing synthetic biology sector. We are witnessing the dawn of the operator's era. Life sciences tools companies are realizing that when replacing biology with synthetic alternatives, the ultimate product is not just the molecule or the polymer—it is the reproducibility. When a company promises to deliver the one thing biology cannot guarantee, manufacturing precision becomes the primary value proposition.

"I am honored and humbled to take on the role of CEO, and I am grateful to the Board for its confidence in me," Dr. Srivastava stated regarding her appointment. "While this is an important transition for the company, our focus remains unchanged: building the business, bringing innovative products to market, growing and retaining our customer base, and delivering meaningful results for our customers and stakeholders. I know this technology, our people, and the work ahead of us, and I am excited about what we can accomplish together."

As cell therapies move from the realm of medical miracles to standardized treatments, the infrastructure supporting them must evolve from artisanal science to industrialized engineering. By placing an operator with deep scale-up expertise at the helm, Slingshot Biosciences is not merely changing leadership; it is aligning its corporate structure with the stringent demands of the clinical future. In the race to cure disease, the victors will be those who can manufacture consistency, day in and day out, without fail.